IL22 and psoriasis: In addition to expected reductions in serum levels of effector cytokines associated with the IL-23/IL-17 and IL-22 pathways, other markers associated with psoriasis were also reduced to a greater extent with guselkumab than with placebo, including CCL22/MDC and CXCL8/IL-8, albeit to a moderate extent.